Mary Wilson
Well-known member
PreProof: Journal pre-proofs are Articles in Press that have been peer reviewed and accepted for publication by the Editorial Board of this publication. ...
Available online 6 February 2025, 100407
https://doi.org/10.1016/j.opresp.2025.1004
Selene Cuenca Peris [SUP]1[/SUP], Margarita Marín Royo [SUP]1[/SUP], Santiago F Marco Domenech [SUP]2[/SUP]
Dear Editor,
COVID-19 disease caused by SARS-COV-2 has been a turning point in the humanity
history. The clinical course has been variable since symptoms like common cold until
bilateral pneumonia1. Radiologically alterations in thoracic CT (computed tomography)
have been ground-glass opacities with or without consolidations, crazy paving or
interlobular septal thickening. The long-term alterations were ground glass, reticular
pattern, traction bronchiectasis and parenchymal bands1,2. If we compare with SARS-
CoV, at 6 months, ground glass was observed in 76%, parenchymal bands in 59%,
reticular pattern in 71% and consolidations in 3%. After 1,5 years, ground glass
disappeared in most patients, persisting in 21% and parenchymal bands in 25%3,4. 15
years after primary infection, only 4% showed radiological alterations5. To date, the risk
factors described in COVID-19 infection associated with persistence of radiological
alterations, including fibrosis, have been advanced age, male sex, type 2 diabetes,
obesity, severity of the disease, smoking and chronic alcoholism4,6,7.
diffusion capacity (DLCO) is the most frequent pulmonary functional alteration described
and is directly related to the severity of the acute disease. The aim of our observational,
prospective, single center study was to describe CT changes during COVID-19
pneumonia and evaluate fibrosis at 6 months describing changes in chest CT and
functional respiratory impairment in all adult patients, non-vaccinate, being discharged
from hospital after COVID-19 pneumonia. For further analysis, according to the findings
of the control thoracic CT 6 months after discharge, patients will be divided into two
groups: group 1 with pulmonary fibrosis and group 2 without pulmonary fibrosis. The
presence on follow-up chest CT of parenchymal bands, irregular interfaces or traction
bronchiectasis will be considered evidence of fibrosis. ...
To conclude, 45% of patients hospitalized for pneumonia secondary to SARS-CoV-2 present signs of fibrosis at 6 months. These findings confirm the need for follow-up of patients over a longer period to clarify whether these changes will persist over time.
more....https://www.sciencedirect.com/scien...?ref=pdf_download&fr=RR-2&rr=90f99fad0c15da47
Available online 6 February 2025, 100407
https://doi.org/10.1016/j.opresp.2025.1004
Selene Cuenca Peris [SUP]1[/SUP], Margarita Marín Royo [SUP]1[/SUP], Santiago F Marco Domenech [SUP]2[/SUP]
Dear Editor,
COVID-19 disease caused by SARS-COV-2 has been a turning point in the humanity
history. The clinical course has been variable since symptoms like common cold until
bilateral pneumonia1. Radiologically alterations in thoracic CT (computed tomography)
have been ground-glass opacities with or without consolidations, crazy paving or
interlobular septal thickening. The long-term alterations were ground glass, reticular
pattern, traction bronchiectasis and parenchymal bands1,2. If we compare with SARS-
CoV, at 6 months, ground glass was observed in 76%, parenchymal bands in 59%,
reticular pattern in 71% and consolidations in 3%. After 1,5 years, ground glass
disappeared in most patients, persisting in 21% and parenchymal bands in 25%3,4. 15
years after primary infection, only 4% showed radiological alterations5. To date, the risk
factors described in COVID-19 infection associated with persistence of radiological
alterations, including fibrosis, have been advanced age, male sex, type 2 diabetes,
obesity, severity of the disease, smoking and chronic alcoholism4,6,7.
diffusion capacity (DLCO) is the most frequent pulmonary functional alteration described
and is directly related to the severity of the acute disease. The aim of our observational,
prospective, single center study was to describe CT changes during COVID-19
pneumonia and evaluate fibrosis at 6 months describing changes in chest CT and
functional respiratory impairment in all adult patients, non-vaccinate, being discharged
from hospital after COVID-19 pneumonia. For further analysis, according to the findings
of the control thoracic CT 6 months after discharge, patients will be divided into two
groups: group 1 with pulmonary fibrosis and group 2 without pulmonary fibrosis. The
presence on follow-up chest CT of parenchymal bands, irregular interfaces or traction
bronchiectasis will be considered evidence of fibrosis. ...
To conclude, 45% of patients hospitalized for pneumonia secondary to SARS-CoV-2 present signs of fibrosis at 6 months. These findings confirm the need for follow-up of patients over a longer period to clarify whether these changes will persist over time.
more....https://www.sciencedirect.com/scien...?ref=pdf_download&fr=RR-2&rr=90f99fad0c15da47
Last edited by a moderator: